| Term 
 | Definition 
 
        | Glucocorticoid replacement; Weak Anti-inflammatory Use: Replacement therapy for adrenal insufficiency Other Drugs: Cortisone (Cortone) - converted to active hydrocortisone in the liver; 80% of effects of hydrocortisone |  | 
        |  | 
        
        | Term 
 
        | Fludrocortisone (generic) |  | Definition 
 
        | Mineral corticoid replacement; Anti-inflammatory Mechanism: Oral synthetic adrenocortical steroid (mineralcorticoid and glucocorticoid activity); similar to aldosterone Use: glucocorticoid replacement therapity in adrenocortical insufficiency; salt losing adrenogenital syndrome |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Anti-inflammatory Mechanism: converted to prednisolone in liver to be active High anti-inflammatory effects with minor salt retaining effects Other drugs: Prednisolone (Delta-Cortef®)               
             Fluticasone (Flovent®, Flonase®)   Budesonide  (Pulmicort®)   Clobetasol (Temovate®)   Clocortolone (Cloderm®)   Mometasone (Nasonex®)   Desonide (Desowen®)  Fluocinonide (Lidex®) |  | 
        |  | 
        
        | Term 
 
        | Aminoglutethimide (Cytadren) |  | Definition 
 
        | Glucocorticoid Mechanism: inhibits conversion of cholesterol to pregnenolone, inhibiting all steroid synthesis Use: Cushings syndrom; metastatic breast and prostate CA Adverse: inhibits estrogen synth, and testosterone synthesis to a lesser degree |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Glucocorticoid Mechanism: inhibits 17a-hydroxylase, inhibit androgens and cortisol synth; eventually inhibits all steroid synthesis Use: Cushings, most effective steroid biosynthesis in pts with cushings  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Glucocorticoid Mechanism: Relatively selective inhibitor of 11a-1-hydroxylase, the terminal enzyme in cortisol synthesis; sustains aldosterone functions;  Use: tests adrenal function and short term symptoms while determining cushing syndrome |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Glucocorticoid Mechanism: Adrenocorticolytic, causes selective atrophy of the zona fasciculata/reticularis of the adrenal gland; binds mitochondrial proteins and inhibits synthesis of corticosteoroids use: Primary adrenal carcinoma; cushings |  | 
        |  | 
        
        | Term 
 
        | Mifepristone (RU 486, Mifeprix®) |  | Definition 
 
        | Glucocorticoid Mechanism: powerful antagonist of progesteron receptors and glucocorticoid receptors at higher doses Use: induce abortion; inoperable pts with ectopic ACTH secretion or adrenal carcinoma who have failed to respond to other therapies |  | 
        |  | 
        
        | Term 
 
        | Spironolactone (Aldactone®) |  | Definition 
 
        | Mineralcorticoid Mechanism: K sparing diuretic, competes with aldosterone for binding sites Use: HTN, hyperaldosteronism (primary), decrease hirsuism in women, treat ascites from cirrhosis |  | 
        |  |